Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022

Cheng ZENG; Jian ZHANG

doi:10.19401/j.cnki.1007-3639.2023.03.006

您当前的位置：

首页 >

文章列表页 >

Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022

Specialists' Commentary | 更新时间：2025-12-31

- Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022
- China Oncology Vol. 33, Issue 3, Pages: 235-240(2023)
- 作者机构：
  
  复旦大学附属肿瘤医院Ⅰ期临床试验病房，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2023.03.006
  CLC： R735.9
- Received：30 January 2023，
  
  Revised：2023-02-23，
  
  Published：30 March 2023
- 稿件说明：
移动端阅览
Cheng ZENG, Jian ZHANG. Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022[J]. China Oncology, 2023, 33(3): 235-240.
DOI：

Cheng ZENG, Jian ZHANG. Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022[J]. China Oncology, 2023, 33(3): 235-240. DOI： 10.19401/j.cnki.1007-3639.2023.03.006.

摘要

胰腺癌是发病率高且生存率低的一种恶性肿瘤，对于缺乏手术适应证及放化疗效果不好的患者，急需发展新型而高效的治疗手段。近年来，抗体药物偶联物（antibody-drug conjugate，ADC）因其高选择性和抗肿瘤活性等优点而逐渐成为研究热点，在胰腺癌的治疗中已取得一些成果，但是仍需面对诸多挑战。本文对2022年度ADC在胰腺癌领域的研究新进展进行综述。

Abstract

Pancreatic cancer is a type of malignant tumor with high incidence and low survival rate. It is urgent to develop novel and efficient therapeutic means for patients lacking surgical indications and patients with poor effects of radiotherapy and chemotherapy. In recent years

antibody-drug conjugate (ADC) has become hot because of their high selectivity and anti-tumor activity. ADC has achieved some results in the treatment of pancreatic cancer

but still face many challenges. This article provided a brief review of the latest developments of ADC in pancreatic cancer in 2022.

关键词

Keywords

references

CABASAG C J , FERLAY J , LAVERSANNE M , et al . Pancreatic cancer: an increasing global public health concern [J ] . Gut , 2022 , 71 ( 8 ): 1686 - 1687 .

HOSEIN A N , BREKKEN R A , MAITRA A . Pancreatic cancer stroma: an update on therapeutic targeting strategies [J ] . Nat Rev Gastroenterol Hepatol , 2020 , 17 ( 8 ): 487 - 505 . DOI: 10.1038/s41575-020-0300-1 http://doi.org/10.1038/s41575-020-0300-1

CHAU C H , STEEG P S , FIGG W D . Antibody-drug conjugates for cancer [J ] . Lancet , 2019 , 394 ( 10200 ): 793 - 804 . DOI: S0140-6736(19)31774-X http://doi.org/S0140-6736(19)31774-X

QI C S , GONG J F , LI J , et al . Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results [J ] . Nat Med , 2022 , 28 ( 6 ): 1189 - 1198 . DOI: 10.1038/s41591-022-01800-8 http://doi.org/10.1038/s41591-022-01800-8

KYUNO D , TAKASAWA A , TAKASAWA K , et al . Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials [J ] . Tissue Barriers , 2022 , 10 ( 1 ): 196 7080.

XU R H , WEI X L , ZHANG D S , et al . A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors [J ] . J Clin Oncol , 2023 , 41 ( 4_suppl ): 352 .

CAZES A , BETANCOURT O , ESPARZA E , et al . A MET targeting antibody-drug conjugate overcomes gemcitabine resistance in pancreatic cancer [J ] . Clin Cancer Res , 2021 , 27 ( 7 ): 2100 - 2110 . DOI: 10.1158/1078-0432.CCR-20-3210 http://doi.org/10.1158/1078-0432.CCR-20-3210

JIN Y B , ZHANG Z H , ZOU S Y , et al . A novel c-MET-targeting antibody-drug conjugate for pancreatic cancer [J ] . Front Oncol , 2021 , 11 : 634881.

GYMNOPOULOS M , BETANCOURT O , BLOT V , et al . TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors [J ] . Mol Oncol , 2020 , 14 ( 1 ): 54 - 68 . DOI: 10.1002/1878-0261.12600 http://doi.org/10.1002/1878-0261.12600

NAKANO T . Systemic treatment of malignant pleural mesothelioma [J ] . Gan To Kagaku Ryoho , 2017 , 44 ( 13 ): 2041 - 2047 .

HASSAN R , BLUMENSCHEIN G R Jr , MOORE K N , et al . First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 16 ): 1824 - 1835 . DOI: 10.1200/JCO.19.02085 http://doi.org/10.1200/JCO.19.02085

SPILIOPOULOU P , KASI A , ABUSHAHIN L I , et al . Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208 [J ] . J Clin Oncol , 2022 , 40 ( 16_suppl ): 4136 . DOI: 10.1200/JCO.2022.40.16_suppl.4136 http://doi.org/10.1200/JCO.2022.40.16_suppl.4136 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4136 https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4136

CUBAS R , ZHANG S , LI M , et al . Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway [J ] . Mol Cancer , 2010 , 9 : 253 . DOI: 10.1186/1476-4598-9-253 http://doi.org/10.1186/1476-4598-9-253

CARDILLO T M , GOVINDAN S V , SHARKEY R M , et al . Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers [J ] . Bioconjug Chem , 2015 , 26 ( 5 ): 919 - 931 . DOI: 10.1021/acs.bioconjchem.5b00223 http://doi.org/10.1021/acs.bioconjchem.5b00223 https://pubs.acs.org/doi/10.1021/acs.bioconjchem.5b00223 https://pubs.acs.org/doi/10.1021/acs.bioconjchem.5b00223

BARDIA A , MESSERSMITH W A , KIO E A , et al . Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial [J ] . Ann Oncol , 2021 , 32 ( 6 ): 746 - 756 . DOI: 10.1016/j.annonc.2021.03.005 http://doi.org/10.1016/j.annonc.2021.03.005 https://linkinghub.elsevier.com/retrieve/pii/S0923753421008838 https://linkinghub.elsevier.com/retrieve/pii/S0923753421008838

YANG M C , SHIA C S , LI W F , et al . Preclinical studies of OBI-999: a novel globo H-targeting antibody-drug conjugate [J ] . Mol Cancer Ther , 2021 , 20 ( 6 ): 1121 - 1132 . DOI: 10.1158/1535-7163.MCT-20-0763 http://doi.org/10.1158/1535-7163.MCT-20-0763 https://aacrjournals.org/mct/article/20/6/1121/673274/Preclinical-Studies-of-OBI-999-A-Novel-Globo-H https://aacrjournals.org/mct/article/20/6/1121/673274/Preclinical-Studies-of-OBI-999-A-Novel-Globo-H

HAN Z W , LYV Z W , CUI B , et al . The old CEACAMs find their new role in tumor immunotherapy [J ] . Invest New Drugs , 2020 , 38 ( 6 ): 1888 - 1898 . DOI: 10.1007/s10637-020-00955-w http://doi.org/10.1007/s10637-020-00955-w

DERY K J , GAUR S , GENCHEVA M , et al . Mechanistic control of carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) splice isoforms by the heterogeneous nuclear ribonuclear proteins hnRNP L, hnRNP A1, and hnRNP M [J ] . J Biol Chem , 2011 , 286 ( 18 ): 16039 - 16051 . DOI: 10.1074/jbc.M110.204057 http://doi.org/10.1074/jbc.M110.204057

TIAN B M , WONG W Y , UGER M D , et al . Development and characterization of a camelid single domain antibody-urease conjugate that targets vascular endothelial growth factor receptor 2 [J ] . Front Immunol , 2017 , 8 : 956 . DOI: 10.3389/fimmu.2017.00956 http://doi.org/10.3389/fimmu.2017.00956

TIAN B , WONG W Y , HEGMANN E , et al . Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer [J ] . Bioconjugate Chem , 2015 , 26 ( 6 ): 1144 - 1155 . DOI: 10.1021/acs.bioconjchem.5b00237 http://doi.org/10.1021/acs.bioconjchem.5b00237

SINGH C S B , EYFORD B A , ABRAHAM T , et al . Discovery of a highly conserved peptide in the iron transporter melanotransferrin that traverses an intact blood brain barrier and localizes in neural cells [J ] . Front Neurosci , 2021 , 15 : 596976.

Views

3819

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

New advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2024

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2023

New progress in basic research, clinical diagnosis and treatment of pancreatic cancer in 2022

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021

Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2020

Related Author

Ting WANG

Yi QIN

Xiaowu XU

Xianjun YU

Tianjiao LI

Longyun YE

Kaizhou JIN

Weiding WU

Related Institution

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai Key Laboratory of Precision Medicine for Pancreatic Cancer, Pancreatic Cancer Institute, Fudan University

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute

复旦大学附属肿瘤医院胰腺外科，复旦大学上海医学院肿瘤学系，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所

AI问答

⁰